By BioStocksElite: Last week Athersys ( ATHX ) announced their quarterly earnings. As a shareholder ..... 2014 is clearly going to be an exciting year for Athersys . MultiStem is Athersys ' main proprietary stem cell technology. Evidence
Athersys ( ATHX ) Q3 2013 Earnings Call November 14 ..... would like to welcome everyone to the Athersys Third Quarter Results Call. [Operator ..... Communications, Investor Relations for Athersys . Thank you for joining today's <br
By Chemistfrog : (Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.) 2013 has proven to be yet another exciting year for the stem cell sector. Clinical trials have yielded exciting results with more hope becoming evident in the many ...
2013, Seeking Alpha published my article Athersys , Inc. Has Blockbuster Potential . Following ..... investors regarding potential valuation for Athersys ( ATHX ) so I wrote follow up article Athersys : Valuation that was published on April 12
BlackbirdAnalytics: I introduced Athersys through two articles titled, " Athersys : A Significantly Undervalued Stem ..... and "A Candid Conversation with Athersys CEO Gil Van Bokkelen." The stock ( ATHX ) was trading at $1.34 when the
By Wall Street Titan : When you enter the website of Osiris Therapeutics ( OSIR ) you are immediately hit with their crowning achievement to date: (click to enlarge) After six years as a public company, Osiris is justified to toot its horn regarding the May 2012 approval for the treatment of acute
We are no longer providing equity research on Athersys ATHX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
estimate intact after reviewing Athersys ' ATHX third-quarter results, a business ..... and financing arrangements. Athersys turned in a net loss of $2.3 ..... sheet. To buoy its cash balance, Athersys has entered into an equity purchase
development of Athersys ' anti-obesity candidate ATHX -105 was put ..... of obesity drug ATHX -105 following ..... clinical risk, Athersys ' MultiStem is ..... company. Although Athersys ' stem cell technology ..... performance of ATHX -105 illustrate
We are putting Athersys ATHX under review in the wake of the company's plummeting share price. Athersys is a development-stage biotech with minimal revenue and negative profits, and equity issuances are key to the firm's survival as it burns